Barr Ellison Solicitors – commercial property
Advertisement: Simpsons Creative
Advertisement: partnersand mid banner
Advertisement: Cambridge Network mid banner
Advertisement: CJBS mid banner
Advertisement: Excalibur Healthcare mid banner
Mid banner advertisement: BDO
Advertisement: EBCam mid banner
Advertisement: RSM mid banner
Advertisement: Mogrify mid banner
Advertisement: Kao Data Centre mid banner
Advertisement: HCR Hewitsons recruitment mid banner
Advertisement mid banner S-Tech 1
ARM Innovation Hub
19 August, 2021 - 20:55 By Tony Quested

Congenica wings into Turkey with distributor deal

Congenica, the Cambridge UK-based digital health business, is stepping up its commercial push in Turkey.

The company, which enables rapid and accurate analysis of complex genomic data to transform people’s lives, has signed a new distribution agreement with ATC Healthcare.

Congenica – based at the Wellcome Trust Sanger Institute at Hinxton – has developed know-how and IP in the field of bioinformatics, genomics, software development and data architecture which it uses to develop commercial clinical decision support platforms using genomic data. 

ATC is a leading Turkish business investing in advanced technologies in the fields of molecular diagnosis and life sciences.

It distributes on behalf of major international providers of molecular diagnostic solutions. Its customers work in academic laboratories and clinical diagnostics and are based across Turkey.

The agreement marks the entry of Congenica’s clinical decision support software into the country, which is a major global market with a population of 84 million people. 

Turkey has a well-established national genome project that aims to sequence 100,000 genomes from healthy individuals as well as from rare and complex disease patients to promote better health for future generations.

ATC will distribute Congenica’s clinical decision support software platform for use in the interpretation of complex genomic data with a focus on rare diseases. 

Congenica’s leading technology platform enables the rapid analysis and interpretation of complex genomic data, allowing the delivery of personalised medicine at scale.

Willem Haagmans, Vice-President Sales EMEA at Congenica, said: “This latest agreement with ATC Healthcare highlights our ongoing expansion into new global markets as we accelerate the rollout of our leading genomic analysis platform.

“Turkey is recognised as a leader in genomics with a strong focus on using clinical genomics to transform healthcare. ATC has an excellent reputation in molecular diagnostics with strong links in the region, which we believe will enable the rapid uptake of Congenica’s software.”

Congenica has established a diverse, global customer-base of hospitals, diagnostic laboratories, academic medical centres and pharmaceutical companies based on its exceptional scientific heritage from the Wellcome Sanger Institute and as the exclusive Clinical Decision Support service provider in the delivery of the ground-breaking UK NHS Genomic Medicine Service.

Congenica’s initial commercial success has led to a customer network spanning 18 countries.

The company raised $50 million Series C funding in November 2020. to advance both its clinical genomic analysis software and its data platform. 

Legal & General was partnered by players from China, Malaysia and Oman in backing the digital health trailblazer. Congenica executives said the cash would drive further commercialisation of rare and inherited cancer applications and expansion into oncology, wellness and pharmaceutical collaborations.

The Series C was co-led by Tencent (China) and Legal & General (UK) and included other new investors Xeraya (Malaysia), Puhua Capital (China) and IDO Investments (Oman). Existing investors Parkwalk, Cambridge Innovation Capital and Downing also participated. Lazard acted as sole financial adviser to the company.

Commenting on the Series C raise, CEO Dr David Atkins, said: “Genomic medicine is revolutionising healthcare, transforming outcomes for patients by providing clinicians with fast, accurate and early diagnoses and the information needed to provide life-changing answers for their patients, improving wellbeing and disease management. 

“This new funding will allow us to build on our established foundation in rare disease and bring the power of our platform to new indications and new markets.”

Newsletter Subscription

Stay informed of the latest news and features